Symbicort® (Budesonide/Formoterol) Pharmacy Program

In November 2019, Kos designed, developed, and implemented the Symbicort® (Budesonide/Formoterol) Pharmacy. AstraZeneca Pty Ltd is pleased to introduce the Program with PharmaPrograms. The primary aim of the Program is to support medication compliance and adherence for both asthma and COPD patients via tailored Quality Use of Medicines (QUM) information.

Valdoxan Patient Program

In November 2019, Kos designed, developed, and implemented the Valdoxan Patient Program with Servier Laboratories (Aust) Pty Ltd). Servier has partnered with PharmaPrograms to provide the Program which supports patients prescribed Valdoxan (agomelatine) tablets. This medication is a private prescription-only medicine used to treat depression in adults including to prevent relapse.

Amgen Pharmacy Partnership in Osteoporosis INTervention (APPOINT) Program

In March 2019, Kos designed, developed, and implemented the Amgen Pharmacy Partnership in Osteoporosis INTervention (APPOINT) Program. Recognising the critical role that pharmacy plays in identifying and treating osteoporosis Amgen Australia has joined with PharmaPrograms to create the Program with the aim of supporting pharmacies to reduce osteoporotic fractures.

Teva Wake Patient Programs

In August 2018 Kos designed, developed, and implemented the Modafinil Patient Screening Program (Modafinil Program) and the Nuvigil® Patient Program (Nuvigil® Program) for Teva Pharma Australia Pty. Ltd. (Teva). It partnered with PharmaPrograms to facilitate the Program through community pharmacies. Modafinil and Nuvigil® (armodafinil) are both listed on the Pharmaceutical Benefits Scheme (PBS). Modafinil and Nuvigil® are two wakefulness-promoting agents for oral administration.

Teva DuoResp® Spiromax® New-to-Therapy Patient Program

In July 2018, Kos designed, developed, and implemented the Teva DuoResp® Spiromax® New-to-Therapy Patient Program (Program) for Teva Pharma Australia Pty. Ltd. (Teva). The program partnered with Community Pharmacy to provide DuoResp Spiromax (budesonide/formoterol) is an inhaled medicine used to treat asthma and chronic obstructive pulmonary disease (COPD).

Astellas Urology Patient Program

In June 2018, Kos designed, developed, and implemented the Astellas Urology Patient Program through community pharmacies. The program was supported by Astellas Pharma Australia Pty. Ltd. in partnership with PharmaPrograms. Patients prescribed Betmiga® (mirabegron) and Vesicare® (solifenacin succinate) are able to participate in this Astellas Urology Patient Program.

Astellas Advagraf® XL Patient Program

In April 2018, Kos designed, developed, and implemented the Advagraf® XL Patient Program with Astellas Pharma Australia Pty. Ltd. and in partnership with PharmaPrograms. Advagraf® XL is a once-daily prolonged-release tacrolimus, an immunosuppressive agent indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

MSD Brenzys Pharmacy Program

In April 2018, Kos designed, developed, and implemented the MSD Brenzys® Pharmacy Program which provides support to patients who have been dispensed Brenzys® (etanercept). Participating patients are eligible to be enrolled in the MSD Harmony™. It is a biosimilar to the reference biological medicine Enbrel© (etanercept).

Osteoporosis Quality Use of Medicines Program

In December 2018, Kos designed, developed, and implemented the Osteoporosis Quality Use of Medicines Program with Amgen Australia. This PharmaPrograms initiative is a single intervention targeted at improving adherence rates among patients prescribed any antiresorptive medication.

Flomaxtra® Patient Program

In April 2019, Kos designed, developed, and implemented the Flomaxtra® Patient Program through community pharmacies. Flomaxtra® (tamsulosin hydrochloride) tablets 0.4mg is an authority Repatriation Pharmaceutical Benefit and a private Prescription-Only Medicine for other patients. It is used to treat men who have symptoms associated with Benign Prostatic Hyperplasia (also known as BPH).